Skip to main content Skip to search Skip to main navigation
News: EMA

EMA: New Q&A Clarify Regulatory Expectations on API Mixes

New Q&A clarify how mixtures of active pharmaceutical ingredients (APIs) and excipients (“API mixes”) should be handled from a regulatory perspective. An API mix is defined as a mixture of an API with one or more excipients and is considered the first step in the manufacture of a finished product.

Submission via an ASMF or CEP may be acceptable in certain cases, particularly when the mixture is required for safety or stability reasons. In such cases, manufacturing may be performed under EU GMP Part II (or Regulation (EU) 2025/2154 for veterinary products). If the mixture is sterile, GMP Part I requirements apply to sterilisation and subsequent steps.

The Q&A also clarify documentation requirements, including justification of excipient choice and levels, stability data where relevant, and transparency regarding the mixing process and control strategy in the dossier.

API mixes justified solely by workability or handling reasons are generally not acceptable.


Source:

EMA: Quality of medicines: questions and answers - Part 1

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next